20/20 Biolabs, Inc. AIDX
NASDAQ · United States · Health Services
$0.4089-0.03 (-6.32%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Sum
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.